Welcome to the 5th Antibody Industrial Symposium 2017 – AIS2017
We are proud to announce the 5th Antibody Industrial Symposium 2017 (AIS2017) that will be held the 27 and 28th of June 2017 in Tours, Loire Valley, France. This congress, jointly organized by the LabEx MAbImprove, Polepharma and MabDesign, is the continuation of the series of Industrial Symposia organized since 2013 (Antibody Biosimilars, MAbDosing, MAbDelivery, and Current and Next Generation Antibody Formats).
The Scientific committee has set-up an exciting program focusing on the following theme: “Antibody-Drug Conjugates: Design & Development for Therapy and Imaging in and beyond Cancer”, with keynote lectures, pitch talks of new creative projects, and industrial talks from leading pharmaceutical companies.
On the one hand, the AIS2017 is the ideal conference for scientists from various horizons, as Antibody-Drug Conjugates (ADCs) bring together people with many skills and various centers of interest, from many types of chemistry to biology through molecular modeling, bioconjugation and much more. On the other hand, the AIS2017 should interest academics as well as industrials, physicians and policy makers to exchange about therapeutic ADCs.
The successive approvals by the FDA of Adcetris® in 2011 and Kadcyla® in 2013 opened the way for many scientists hoping to reach Paul Ehrlich’s magic bullet vision. Indeed, an ADC results from the grafting of a powerful cytotoxic agent on a therapeutic antibody (MAb) through a judiciously constructed spacer arm (linker). It is a vectorized therapy which tackles the challenge to harness both strength of the selectivity of the MAb for its target and high potency of the payload against the malignancy. Therefore, it is not surprising that the topics covered in this symposium will be excitingly very wide: after an overview presentation of the area of research of ADCs, the search for new targets will be presented, opening the way either for new fields of applications of ADC in oncology and beyond, or for diagnostic purposes. Then, several approaches, ranking from new linkers to new payloads through new bioconjugation techniques, will enable the development of the next generation ADC. Such ADC will offer new challenges for their developability, scale-up and manufacturing, before going to the clinic, where their safety and efficacy will be assessed, to offer hopefully new opportunities for the treatment of patients who are non-responsive, resistant or relapsed.
To share the thrill about this new class of biodrugs, the program contains several opportunities for networking and for companies to showcase their new products and technologies, and dedicated time for business partnering.
The Symposium will take place at the Vinci International Convention Centre in the heart of Tours, providing easy transport link, and plenty of accommodation close to the venue.
Looking forward to welcoming you to the 5th Antibody Industrial Symposium 2017 in Tours.
The Scientific Committee, the LabEx MAbImprove, MabDesign and Polepharma